[Multimodal laryngeal preservation: current data-based opinion].

[1]  G. Calais,et al.  Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Hoppe,et al.  Docetaxel, cisplatin (TP), and radiation with or without cetuximab in advanced larynx carcinoma (DeLOS II trial). , 2010 .

[3]  D. Niederwieser,et al.  Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay. , 2010 .

[4]  Warren D D'Souza,et al.  The minimum knowledge base for predicting organ-at-risk dose–volume levels and plan-related complications in IMRT planning , 2010, Physics in medicine and biology.

[5]  I. Bechmann,et al.  Assay-based response evaluation in head and neck oncology: requirements for better decision making , 2010, European Archives of Oto-Rhino-Laryngology.

[6]  G. Calais,et al.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. , 2009, Journal of the National Cancer Institute.

[7]  J. Werner,et al.  Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial) , 2009, European Archives of Oto-Rhino-Laryngology.

[8]  Arnold Knijn,et al.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. , 2009, European journal of cancer.

[9]  A. Dietz,et al.  Long-term results of a prospective multicenter phase II study to preserve the larynx function using concomitant boost radiochemotherapy with Carboplatin. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  N. Aaronson,et al.  Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Garden,et al.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Garden,et al.  TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. , 2007, The Lancet. Oncology.

[13]  C. Tsien,et al.  Chemo-selection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma , 2007 .

[14]  J. Pignon,et al.  Altered fractionated radiotherapy in head and neck cancer – Authors' reply , 2006, The Lancet.

[15]  K. Ang,et al.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis , 2006, The Lancet.

[16]  T. Pajak,et al.  Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Tesch,et al.  TPF induction chemotherapy followed by concurrent radiochemotherapy in the first line therapy of advanced carcinomas of the larynx and pharynx (phase IIb trial). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Avraham Eisbruch,et al.  Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Grandis,et al.  Head and neck cancer: recent advances and new standards of care. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Eisbruch,et al.  Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Carles,et al.  Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F Berrino,et al.  EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  R. Weber,et al.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.

[24]  K. Bratengeier,et al.  Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas--a possibility for organ preservation. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  A. Dietz,et al.  Organerhalt beim fortgeschrittenen Larynx- bzw. Hypopharynxkarzinom durch primäre Radiochemotherapie Ergebnisse einer multizentrischen Phase-II-Studie , 2002, HNO.

[26]  J. Bourhis,et al.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data , 2000, The Lancet.

[27]  W. Mendenhall.  T3-4 squamous cell carcinoma of the larynx treated with radiation therapy alone. , 1998, Seminars in radiation oncology.

[28]  Susan G. Fisher,et al.  Long-term Quality of Life After Treatment of Laryngeal Cancer , 1998 .

[29]  A. Dietz,et al.  Das chronische Larynxödem als Spätreaktion nach Radiochemotherapie , 1998, HNO.

[30]  W. Hong,et al.  Functional outcomes following treatment for advanced laryngeal cancer. Part I--Voice preservation in advanced laryngeal cancer. Part II--Laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Gr , 1998, The Annals of otology, rhinology & laryngology. Supplement.

[31]  L. Tuason,et al.  A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results , 1997, Head & neck.

[32]  L. Collette,et al.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. , 1996, Journal of the National Cancer Institute.

[33]  R. Shaker,et al.  Deglutitive aspiration in patients with tracheostomy: effect of tracheostomy on the duration of vocal cord closure. , 1995, Gastroenterology.

[34]  P. Rubin,et al.  RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. , 1995, International journal of radiation oncology, biology, physics.

[35]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[36]  E. A. Mohide,et al.  Postlaryngectomy quality-of-life dimensions identified by patients and health care professionals. , 1992, American journal of surgery.

[37]  W. Hong,et al.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. , 1991, The New England journal of medicine.

[38]  D. Jones,et al.  The recording of morbidity related to radiotherapy. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  M. Bischof,et al.  Kopf-Hals-Tumoren , 2013 .

[40]  K. Ang,et al.  Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. , 2009, International journal of radiation oncology, biology, physics.

[41]  S. Bentzen,et al.  The need for adverse effects reporting standards in oncology clinical trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Fabrice Denis,et al.  Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. , 2003, International journal of radiation oncology, biology, physics.

[43]  J. Ensley,et al.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.